DESIGN AND POWERING OF CYSTIC FIBROSIS CLINICAL TRIALS USING RATE OF FEV1 DECLINE AS AN EFFICACY ENDPOINT

摘要

BackgroundRate of lung function decline (RLFD) (as FEV1 percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements.